Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| T-817 SCHEMBL30574118 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL47926 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL27025 | 0.95 | SIGMAR1 (0.91) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| Hydrochloric Acid SCHEMBL47954 | 0.94 | SIGMAR1 (0.89) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL47923 | 0.93 | SIGMAR1 (0.87) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL4134384 | 0.93 | SIGMAR1 (0.86) | SIGMAR1CYP2A6OPRM1OPRK1HCRTR1 | |
| T-817 SCHEMBL48195 | 0.93 | SIGMAR1 (0.86) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL48249 | 0.92 | SIGMAR1 (0.85) | SIGMAR1CYP2A6OPRM1OPRK1HRH3 | |
| Hydrochloric Acid SCHEMBL47938 | 0.92 | SIGMAR1 (0.85) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL48064 | 0.92 | SIGMAR1 (1.00) | SIGMAR1CYP2A6OPRM1OPRK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951092-B2 | Agent for preventing or treating brain atrophy | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2024-04-09 | — | — | US | claimed |
| US-20230346745-A1 | AGENT FOR PREVENTING OR TREATING TAUOPATHY | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | claimed |
| US-20230310371-A1 | AGENT FOR REDUCING AMOUNT OF AMYLOID B PROTEIN | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | claimed |
| EP-3563847-B1 | PHARMACEUTICAL COMPOSITION | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2023-09-20 | — | — | EP | claimed |
| EP-3705121-B1 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2023-08-30 | — | — | EP | claimed |
| CN-116492335-A | Agent for preventing or treating brain atrophy | 富士胶片富山化学株式会社 | 2023-07-28 | — | — | CN | claimed |
| CN-116473962-A | Agent for preventing or treating brain atrophy | 富士胶片富山化学株式会社 | 2023-07-25 | — | — | CN | claimed |
| EP-3563846-B1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2023-07-19 | — | — | EP | claimed |
| US-11666551-B2 | Agent for reducing amount of amyloid β protein | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | claimed |
| US-11660287-B2 | Agent for preventing or treating spinocerebellar ataxia | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-05-30 | — | — | US | claimed |
| EP-2287160-A1 | NOVEL BENZOTHIOPHENE OXIDE DERIVATIVE AND SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | claimed |
| EP-2210884-A2 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propionic acid and 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol as well as salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-28 | — | — | EP | claimed |
| US-20100184997-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-22 | — | — | US | claimed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | claimed |
| US-20090209512-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | claimed |
| EP-2048145-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2009-04-15 | — | — | EP | claimed |
| US-20090093453-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD (JP) | 2009-04-09 | — | — | US | claimed |
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD (JP) | 2009-03-12 | — | — | US | claimed |
| EP-2011796-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-01-07 | — | — | EP | claimed |
| EP-1864978-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | PMP22, ACOX1, PAOX | SIGMAR1 1914/4885CYP2A6 1393/4885OPRM1 557/4885 |
| US-20100184997-A1 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF | PRKCH, PRKCA, PRKCB | SIGMAR1 3434/4885CYP2A6 4551/4885OPRM1 3599/4885 |
| US-20090093453-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | NGF, GAP43, BDNF | SIGMAR1 2156/4885CYP2A6 3976/4885OPRM1 1130/4885 |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | SIGMAR1 2529/4885CYP2A6 3200/4885OPRM1 3166/4885 |
| US-20090209512-A1 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF | NGF, GAP43, BDNF | SIGMAR1 2156/4885CYP2A6 3976/4885OPRM1 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.